George Bickerstaff Sells 20,000 Shares of CareDx (NASDAQ:CDNA) Stock

Posted by George Bondi on Aug 8th, 2026

CareDx, Inc. (NASDAQ:CDNA – Get Free Report) Director George Bickerstaff sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $46.28, for a total transaction of $925,600.00. Following the completion of the sale, the director directly owned 134,061 shares of the company’s stock, valued at $6,204,343.08. The trade was a 12.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

CareDx Stock Performance

NASDAQ CDNA opened at $46.69 on Friday. The company has a market cap of $2.42 billion, a PE ratio of 22.56 and a beta of 2.39. The firm’s 50 day moving average price is $31.01 and its 200-day moving average price is $23.52. CareDx, Inc. has a 52-week low of $11.27 and a 52-week high of $49.76.

CareDx (NASDAQ:CDNA – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.37 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.14. The company had revenue of $131.95 million during the quarter, compared to the consensus estimate of $114.05 million. CareDx had a net margin of 24.23% and a return on equity of 2.87%. CareDx’s revenue for the quarter was up 52.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.16) earnings per share. On average, analysts forecast that CareDx, Inc. will post 0.47 earnings per share for the current fiscal year.

Institutional Trading of CareDx

Institutional investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD raised its stake in CareDx by 1.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 39,218 shares of the company’s stock worth $739,000 after acquiring an additional 711 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of CareDx by 4.8% in the second quarter. The Manufacturers Life Insurance Company now owns 27,742 shares of the company’s stock valued at $542,000 after purchasing an additional 1,280 shares during the period. Quarry LP acquired a new position in shares of CareDx in the fourth quarter valued at about $25,000. Allspring Global Investments Holdings LLC raised its stake in shares of CareDx by 9.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 19,091 shares of the company’s stock worth $365,000 after purchasing an additional 1,675 shares during the last quarter. Finally, SG Americas Securities LLC raised its stake in shares of CareDx by 8.3% in the first quarter. SG Americas Securities LLC now owns 29,949 shares of the company’s stock worth $520,000 after purchasing an additional 2,292 shares during the last quarter.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on CDNA shares. Weiss Ratings upgraded CareDx from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. William Blair upgraded shares of CareDx to a “hold” rating in a report on Thursday, July 16th. Wall Street Zen upgraded shares of CareDx from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 3rd. Craig Hallum upgraded shares of CareDx from a “hold” rating to a “buy” rating and set a $64.00 price target on the stock in a report on Monday, August 3rd. Finally, HC Wainwright restated a “neutral” rating and issued a $46.00 price target on shares of CareDx in a report on Friday, July 31st. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, CareDx currently has a consensus rating of “Hold” and a consensus target price of $47.75.

Read Our Latest Research Report on CDNA

About CareDx

(Get Free Report)

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.